LeadCare® II is the only CLIA-waived, point-of-care lead testing system that makes it possible to test, educate and intervene on-the-spot, in one visit. No need to send patients to an outside lab. No need to re-test due to sample problems at the lab. No risk of losing track of a child who needs treatment.
Who should be tested?
Federal law requires that all Medicaid eligible children be tested at 12 and 24 months and ages 36 to 72 months if they have not previously been tested.
Each state has guidelines for blood lead testing. The American Academy of Pediatrics (AAP) recommends that “children should be tested at least once when they are 2 years of age or, ideally, twice, at 1 and 2 years of age, unless lead exposure can be confidently excluded.”4
Contact us for information to help you determine your state’s specific testing requirements.
Who is at risk for lead exposure? Children are considered at risk if any of the following are true4:
• Child lives in or frequently visits a home built before 1950, or a recently renovated home built before 1978
• Child has a sibling or frequent playmate with elevated blood lead levels
• Child's parent or primary caregiver works with lead. Examples include: battery recycling or manufacture, lead smelting, lead mining, auto repair, shipbuilding, construction, plumbing, and glass manufacture5
• Child is a recent immigrant, refugee, or foreign adoptee.
• Child has a household member who uses traditional, folk, or ethnic remedies or cosmetics or who routinely eats food imported informally (e.g., by a family member)
No safe levels. Evidence continues to grow that blood lead levels as low as 5 ug/dL may impair cognition3, with no minimum threshold yet identified.
Lifelong consequences of lead exposure include:
• Six times higher likelihood of having a reading disability6
• Being seven times more likely to drop out of high school6
• Lower scores on neurobehavioral development7
• Lower scores on tests for math, reading, nonverbal reasoning and short term memory7
• Hypertension that contributes to adult cardiovascular disease8
• Decline in IQ with every 1.0 μg/dL increase in blood lead9
Early diagnosis helps to quickly address the effects of lead exposure and provides impetus for lead abatement in homes.
LeadCare II is the only CLIA-waived point-of-care blood lead testing system. Employees of an office or lab operating under a CLIA Certificate of Waiver can administer the test.